Gsa Capital Partners LLP Clearside Biomedical, Inc. Transaction History
Gsa Capital Partners LLP
- $1.11 Billion
- Q1 2025
A detailed history of Gsa Capital Partners LLP transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 201,589 shares of CLSD stock, worth $98,778. This represents 0.02% of its overall portfolio holdings.
Number of Shares
201,589Holding current value
$98,778% of portfolio
0.02%Shares
16 transactions
Others Institutions Holding CLSD
# of Institutions
50Shares Held
11MCall Options Held
5.9KPut Options Held
86.6K-
Vanguard Group Inc Valley Forge, PA2.81MShares$1.38 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$1.08 Million3.43% of portfolio
-
Carmignac Gestion Paris, I01.51MShares$739,0870.02% of portfolio
-
Black Rock Inc. New York, NY798KShares$391,0870.0% of portfolio
-
Geode Capital Management, LLC Boston, MA792KShares$388,2010.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $29.5M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...